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Pulmonary toxicity after intraperitoneal
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complication of HIPEC
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Abstract
Background: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has
become a common treatment approach for disseminated appendiceal neoplasms. Systemic absorption of
intraperitoneal chemotherapeutics may lead to drug-induced toxicity, most commonly neutropenia. Mitomycin C
has been the most commonly used chemotherapeutic in HIPEC for the past several decades.
Case presentation: Here, we describe a rare pulmonary complication secondary to intraperitoneal administration
of mitomycin C.
Conclusions: While rare, intraperitoneal mitomycin C has the potential to cause serious pulmonary toxicity that
should be considered with administration. To our knowledge, this report represents only the second case described
in the literature.
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Background
Aggressive surgical approaches to patients with periton-
eal carcinomatosis from nongynecologic malignancies
have become increasingly common, abrogating some of
the historic nihilism associated with treating this difficult
patient population [1]. Specifically, over the last three
decades, cytoreductive surgery combined with hyper-
thermic intraperitoneal chemotherapy (CRS/HIPEC) has
emerged as a viable treatment option for selected pa-
tients with reasonable morbidity and favorable oncologic
outcomes [1, 2].
In patients with disseminated colorectal and appendi-
ceal malignancies undergoing CRS/HIPEC, mitomycin C
(MMC) has been the preferred chemotherapeutic agent
for decades [3–6]. It is a large molecule with limited sys-
temic absorption, it rapidly penetrates tumor cells, and
it is synergistic with hyperthermia [7, 8]. The most com-
mon toxicity associated with MMC in HIPEC is neutro-
penia, which has been shown to occur in up to 39 % of
patients [9, 10]. Intravenous MMC is well-known to
cause dose-dependent interstitial lung disease, but re-
ports of pulmonary toxicity secondary to intraperitoneal
administration are rare [11–13]. Here, we present a case
of acute respiratory distress syndrome (ARDS) secondary
to MMC administration in a patient recovering from
CRS/HIPEC for disseminated appendiceal cancer.
Case presentation
A 38-year-old female with an unremarkable past medical
history initially presented to an outside facility with
acute-onset low back pain. MRI showed a fluid-filled ap-
pendix, and a subsequent CT scan raised concern for
acute appendicitis. A laparoscopic appendectomy was
performed on the 11th of August 2015 with intraopera-
tive findings of a swollen appendix without any evidence
of rupture. Frozen section of the specimen revealed at
least low-grade dysplasia with negative margins, and the
procedure was terminated at that point. Final pathology
revealed invasive adenocarcinoma with evidence of per-
foration and normal mesoappendix making this a T4Nx
tumor. Peritoneal washings revealed tumor cells present.
The patient was then referred to our institution for
consideration of CRS/HIPEC. After multidisciplinary
tumor board discussion, the patient underwent 3 months
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of XELOX therapy with plans for interval CRS/HIPEC.
In January 2016, the patient underwent laparoscopic
right hemicolectomy, omentectomy, and HIPEC. Prior
to incision, 1 g of ertapenem was given per routine. No
gross disease was appreciated on exploration. The place-
ment of the HIPEC cannulae was performed through the
laparoscopic extraction site of the colon and omentum,
essentially facilitating a minimally invasive HIPEC. Per
institutional practice, HIPEC involved administration of
40 mg MMC with a target intraperitoneal temperature
of 41 °C for 90 min. Per institutional protocol, mitomy-
cin C is given at a fixed dose and not dosed by body sur-
face area. Thirty milligrams is administered at time
0 min, and 10 mg administered at time 60 min. Total
perfusate is 3 L of normal saline.
During the operation, the patient received 2.2 L of
total fluid, primarily lactated Ringer’s solution, over the
course of 5 h. No blood products were given, and the
patient made 265 mL of urine during the case with an
estimated blood loss of 50 mL. The patient’s fluid bal-
ance over the next 24 h was essentially even, 2.5 L of sa-
line and 1.8 L of urine output recorded. No blood
products were given postoperatively either.
On postoperative day 2, the patient developed acute
respiratory distress with increasing oxygen requirements.
She was febrile to 39.5 ° C and acutely tachycardic, with
a heart rate of 143 bpm. She was placed on a partial re-
breather and transferred to the surgical ICU. A CT scan
was obtained, which ruled out pulmonary embolism but
showed marked edema and infiltration of the lungs
(Fig. 1). The patient was started on vancomycin/pipera-
cillin-tazobactam/azithromycin for presumed pneumo-
nia. She was given 20 mg furosemide intravenously with
excellent diuresis. She received an additional dose on
postoperative day 3. Nasal swab for respiratory syncytial
virus and Legionella and Strep pneumoniae urine antigen
studies were sent and ultimately returned as negative,
and WBCs were within normal limits throughout this
event. Additional studies including sputum and blood
cultures were all negative.
On postoperative day 4, the patient’s respiratory status
continued to worsen despite the use of intermittent bi-
lateral positive airway pressure (BiPAP), ultimately re-
quiring intubation. Phenylephrine was also administered
for blood pressure support. At this time, chest X-ray
showed increasing pulmonary opacities (Fig. 2). The pul-
monology service was consulted on postoperative day 5,
and their team concluded that this patient had ARDS of
uncertain etiology given negative infectious workup to
date. Bronchoscopy was recommended if the patient
failed to improve.
However, following intubation, the patient rapidly im-
proved and was extubated by postoperative day 7. Though
she remained essentially afebrile from postoperative day 2
until discharge (Tmax no greater than 38 C), empiric anti-
biotics were continued until discharge, with discontinu-
ation of azithromycin on postoperative day 7. Repeated
chest X-ray was obtained and showed marked improve-
ment (Fig. 3). The patient continued to improve with no
complications following extubation and was discharged
home on postoperative day 10 without need of supple-
mental oxygen, tolerating a regular diet, and with return
of bowel function.
At no point during the postoperative course was there
ever any evidence of abdominal sepsis to explain the
Fig. 1 Chest CT with IV contrast obtained at the onset of respiratory
insufficiency, showing new diffuse bilateral heterogeneous and
consolidative opacities with small right greater than left pleural
effusions, consistent with ARDS
Fig. 2 Frontal projection chest X-ray taken at onset of respiratory
insufficiency, showing diffuse bilateral heterogeneous opacities
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pulmonary findings. Throughout her postoperative
course, her abdomen remained appropriately soft; she
had an early return of bowel function, with no clinical
evidence of peritonitis. Furthermore, an abdominal CT
scan done at the onset of respiratory insufficiency on
postoperative day 2 showed normal postsurgical
changes, but no fluid collection or other evidence of
anastomotic leak, making an abdominal source for her
pulmonary toxicity unlikely.
The patient experienced mild neutropenia 5 days fol-
lowing the onset of respiratory distress, which resolved
within a few days. Prior to her operation, the patient had
a white blood cell count of 3.9 × 109 cells/L, which in-
creased within the normal range to 7.9 × 109 at the onset
of respiratory insufficiency. Her white blood cell count
then progressively decreased to a mild neutropenia,
reaching 2.6 × 109 by postoperative day 7. At the time of
her discharge her neutropenia had resolved, with a count
of 8.0 × 109.
At the patient’s most recent follow-up appointment,
over 1 month postoperatively, she reported no short-
ness of breath or chest pain, with an oxygen saturation of
99 % on room air with a respiratory rate of 16. Overall,
she is doing well from a respiratory standpoint. She is
scheduled to restart systemic chemotherapy.
Conclusions
Cytoreductive surgery in combination with HIPEC is a
well-accepted and increasingly utilized treatment strategy
for patients with disseminated appendiceal malignancies.
MMC is the most frequently used chemotherapeutic agent
for this approach, in part due to its high molecular weight
that allows for limited systemic penetration [13]. Unlike
conventional systemic chemotherapy for appendiceal can-
cer, which has limited access to the peritoneum, MMC
HIPEC allows for high local doses targeted at residual
micrometastatic peritoneal disease [7, 14]. The hyperther-
mia used in HIPEC synergizes with the antitumor effects
of intraperitoneal chemotherapy by increasing cytotoxicity
as well as the depth of penetration by the drug [7].
Although this strategy has favorable oncologic out-
comes compared to systemic chemotherapy alone,
CRS/HIPEC carries potential for significant adverse
effects. Morbidity following this treatment is most
commonly related to cytoreductive surgery; yet, there
remains a risk for MMC-related toxicity [13]. The
most frequent side effect from peritoneal MMC is
neutropenia, for which female sex and MMC dose
per body surface area have been implicated as risk
factors [9]. The patient presented in this case, al-
though she had a significant drop in white blood cell
count resulting in a Grade 2 leukocyte toxicity (from
7.2 × 109 to 2.5 × 109), did not experience neutropenia
(ANC 2.2 × 109) [15]. Of note, she also had a signifi-
cant drop in her hemoglobin to a Grade 3 anemia
(10.4 to 7.3 g/dL) without significant blood loss [15].
More notable and unique in this case was the onset
of respiratory symptoms after treatment with MMC.
This patient was ultimately diagnosed with ARDS be-
ginning 2 days post-therapy due to a constellation of
factors that include acute-onset respiratory insuffi-
ciency with an FiO2/paO2 of 250, bilateral pulmonary
infiltrates on imaging, and lack of cardiogenic path-
ology. The presence of a degree of myelosuppression
in this patient, as evidenced by the drop in her ANC
and hematocrit postoperatively, confirms an element
of systemic absorption of MMC, which supports the
diagnosis of MMC toxicity-induced ARDS. Given the
negative infectious workup, a noninfectious cause for
ARDS in this patient was strongly favored. The strong
temporal relationship with administration of intraperi-
toneal mitomycin C and development of pulmonary
toxicity also favors drug toxicity as the inciting cause
for ARDS. Given the well-established relationship be-
tween systemic mitomycin C and development of
interstitial pneumonitis, the pulmonary and critical
care teams strongly favored this diagnosis. However,
given the patient’s relatively rapid recovery, no lung
biopsy was performed and empiric steroid therapy
was never instituted.
A recent study on the neutropenic effects of MMC
HIPEC resulted in a standardized, weight-based algo-
rithm dosing system adjusted for the presence of
prior systemic chemotherapy to minimize neutropenia
[9]. This patient received a dose of MMC HIPEC
consistent with this algorithm. While she did not de-
velop neutropenia, we believe that the development of
ARDS in addition to an evidence of myelosuppression
is both attributable to intraperitoneal administration
Fig. 3 Repeated chest X-ray 5 days later, with improving
bilateral opacities
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of MMC. Unique to this patient is her BMI being
<20 (19.3) and her body surface area being only
1.61 m2. Side effects of MMC HIPEC are reported to
happen at a median BMI of 25.5 (range 19–36.2) and
BSA of 1.77 (range 1.39–2.36) [9].
The first cases of interstitial pneumonitis during treat-
ment with intravenous MMC were reported in 1978
[16]. Following this publication, pulmonary toxicity con-
tinued to be reported as a rare but well-known side ef-
fect of MMC, with occurrence rates of 5 to 12 % [17].
The first prospective study on the relationship between
intravenous MMC and pulmonary toxicity concluded
that this toxicity is a dose-dependent side effect of
MMC that should be considered only when patients re-
ceive over a 20 mg/m2 cumulative dose [18]. This model
was supported by later pharmacological evidence that
there is a direct relationship between body surface area
and MMC plasma clearance, as well as between plasma
exposure and hematological toxicity [14]. Recommenda-
tions of this study were to use a dose of 25 mg/m2, di-
vided into three portions of 50 % at the beginning of
treatment, 25 % after 30 min, and 25 % after another
30 min, in order to limit the incidence of leukopenic side
effects to 10 %.
Despite the established relationship between intraven-
ous MMC and interstitial pneumonitis, large studies of
MMC HIPEC-induced pulmonary toxicity have yet to be
reported in the literature. A 2008 report outlined the
first published case of HIPEC MMC-induced interstitial
pneumonitis in a patient who received 30.8 mg/m2
HIPEC MMC within the standard treatment dosing pa-
rameters [13]. This case similarly demonstrated systemic
penetration of MMC despite dosing according to estab-
lished guidelines. Unlike the patient presented here,
however, the previous case describes a case of interstitial
pneumonitis 37 days following therapy, requiring ste-
roids but without need for intubation. Both accounts
draw attention to the potential for respiratory toxicity
associated with HIPEC MMC.
It remains unclear what, if any, underlying factors
may have predisposed these patients to acquire re-
spiratory insufficiency, but the existence of such fac-
tors could/may help providers better predict which
patients are vulnerable to these side effects. Although
rare, it is clear that oncologists must be aware of the
potential for pulmonary toxicity of MMC, which we
have seen possible with either intravenous or intra-
peritoneal administration. These events should be
monitored for and treated aggressively, and further
cases must continue to be reported to bring insight
to the mechanisms that underlie this process, which
patients may be at increased risk, and how dosing of
HIPEC MMC might be altered to avoid further
complications.
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